Tilray Brands, Inc.

SWX:2HQ Stock Report

Market Cap: CHF 7.1b

Tilray Brands Valuation

Is 2HQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 2HQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 2HQ (CHF46.28) is trading above our estimate of fair value (CHF7.74)

Significantly Below Future Cash Flow Value: 2HQ is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2HQ?

Key metric: As 2HQ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2HQ. This is calculated by dividing 2HQ's market cap by their current revenue.
What is 2HQ's PS Ratio?
PS Ratio10.6x
SalesUS$830.77m
Market CapUS$8.83b

Price to Sales Ratio vs Peers

How does 2HQ's PS Ratio compare to its peers?

The above table shows the PS ratio for 2HQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.1x
COPN Cosmo
10.9x26.71%CHF 1.1b
DESN Dottikon ES Holding
8.3x13.23%CHF 3.6b
NWRN Newron Pharmaceuticals
13.9x38.17%CHF 245.9m
SDZ Sandoz Group
3.3x5.10%CHF 29.9b
2HQ Tilray Brands
10.6x4.37%CHF 8.8b

Price-To-Sales vs Peers: 2HQ is expensive based on its Price-To-Sales Ratio (10.6x) compared to the peer average (6.8x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 2HQ's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

18 CompaniesPrice / SalesEstimated GrowthMarket Cap
2HQ 10.6xIndustry Avg. 4.1xNo. of Companies23PS048121620+
18 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 2HQ is expensive based on its Price-To-Sales Ratio (10.6x) compared to the European Pharmaceuticals industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is 2HQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2HQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.6x
Fair PS Ratio2.6x

Price-To-Sales vs Fair Ratio: 2HQ is expensive based on its Price-To-Sales Ratio (10.6x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2HQ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
CHF 14.16
0%
31.28%CHF 19.85CHF 6.75n/a9
Jul ’27n/a
CHF 14.16
0%
31.28%CHF 19.85CHF 6.75n/a9
Jun ’27n/a
CHF 14.16
0%
31.28%CHF 19.85CHF 6.75n/a9
May ’27n/a
CHF 14.16
0%
31.28%CHF 19.85CHF 6.75n/a9
Apr ’27n/a
CHF 14.16
0%
31.28%CHF 19.85CHF 6.75n/a9
Mar ’27n/a
CHF 14.16
0%
31.28%CHF 19.85CHF 6.75n/a9
Feb ’27n/a
CHF 14.16
0%
31.28%CHF 19.85CHF 6.75n/a9
Jan ’27n/a
CHF 14.16
0%
31.28%CHF 19.85CHF 6.75n/a9
Dec ’26CHF 462.80
CHF 14.16
-96.94%
31.28%CHF 19.85CHF 6.75n/a9
Nov ’26CHF 462.80
CHF 14.29
-96.91%
31.28%CHF 20.03CHF 6.81n/a9
Oct ’26CHF 462.80
CHF 7.83
-98.31%
43.21%CHF 15.92CHF 4.78n/a9
Sep ’26CHF 462.80
CHF 7.93
-98.29%
43.21%CHF 16.14CHF 4.84n/a9
Aug ’26CHF 462.80
CHF 7.56
-98.37%
34.31%CHF 12.08CHF 4.83n/a9
Jul ’26CHF 462.80
CHF 10.55
-97.72%
41.94%CHF 20.00CHF 4.80n/a12
Jun ’26CHF 462.80
CHF 10.68
-97.69%
41.58%CHF 20.63CHF 4.95n/a13
May ’26CHF 462.80
CHF 10.68
-97.69%
41.58%CHF 20.63CHF 4.95n/a13
Apr ’26CHF 462.80
CHF 15.83
-96.58%
28.26%CHF 26.52CHF 8.84n/a13
Mar ’26CHF 462.80
CHF 16.46
-96.44%
24.41%CHF 27.08CHF 11.29n/a14
Feb ’26CHF 462.80
CHF 16.69
-96.39%
24.41%CHF 27.45CHF 11.44n/a14
Jan ’26CHF 462.80
CHF 19.55
-95.78%
27.45%CHF 35.92CHF 15.27n/a13
Dec ’25CHF 462.80
CHF 19.54
-95.78%
26.56%CHF 35.53CHF 15.54CHF 462.8013
Nov ’25CHF 462.80
CHF 18.96
-95.90%
26.17%CHF 34.29CHF 15.00CHF 462.8013
Oct ’25CHF 462.80
CHF 19.58
-95.77%
23.81%CHF 33.85CHF 16.08CHF 462.8014
Sep ’25CHF 462.80
CHF 20.58
-95.55%
24.73%CHF 34.61CHF 16.44CHF 462.8014
Aug ’25CHF 462.80
CHF 20.77
-95.51%
24.73%CHF 34.94CHF 16.60CHF 462.8014
Jul ’25CHF 462.80
CHF 21.34
-95.39%
22.76%CHF 35.95CHF 17.08CHF 462.8017
CHF 105.49
Fair Value
56.1% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/02 14:23
End of Day Share Price 2025/11/27 00:00
Earnings2025/08/31
Annual Earnings2025/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tilray Brands, Inc. is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Jesse PytlakATB Cormark Historical (Cormark Securities)